SJS Investment Consulting’s Definium Therapeutics DFTX Stock Holding History

SJS Investment Consulting’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189	Buy	+4	New	+$99	﹤0.01%	2488
2024 Q4	–	Sell	-12	Closed	-$69	–	1667
2024 Q3	$69	Hold	12	–	–	﹤0.01%	1595
2024 Q2	$87	Hold	12	–	–	﹤0.01%	1587
2024 Q1	$113	Sell	12 -2	-14%	-$11	﹤0.01%	1561
2023 Q4	$52	Hold	14	–	–	﹤0.01%	1589
2023 Q3	$44	Hold	14	–	–	﹤0.01%	1598
2023 Q2	$50	Hold	14	–	–	﹤0.01%	1561
2023 Q1	$45	Hold	14	–	–	﹤0.01%	1527
2022 Q4	$31	Buy	14 +12	+600%	+$33	﹤0.01%	1564
2022 Q3	$0	Buy	+2	New	+$19	﹤0.01%	1342
2022 Q1	$0	Sell	2 -267	-99%	-$4.63K	﹤0.01%	1105
2021 Q4	$6K	Buy	+269	New	+$8.59K	﹤0.01%	410

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SJS Investment Consulting's DFTX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 4 shares worth $189. The stake represents ﹤0.01% of the portfolio and ranks #2488 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in DFTX as recently as Q3 2024.

SJS Investment Consulting first reported a position in DFTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $6K in Q4 2021. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

SJS Investment Consulting held 4 shares of Definium Therapeutics worth $189 as of Q2 2026.
Definium Therapeutics was a new SJS Investment Consulting position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2488 holding.
SJS Investment Consulting first reported a position in Definium Therapeutics in Q4 2021 and has held it in 12 quarters since.
SJS Investment Consulting's Definium Therapeutics position peaked at $6K in Q4 2021.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.